Mark A. Hlatky, MD; Dena M. Bravata, MD, MS
Hlatky MA, Bravata DM. Review: Rosiglitazone increases risk for MI but does not differ from other drugs for CV death in type 2 diabetes. ACP J Club. 2007;147:66. doi: 10.7326/ACPJC-2007-147-3-066
Download citation file:
Published: ACP J Club 2007;147(3):66.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use